Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048580 | 0.89 | HTR6 (0.58) | HTR6POLBCYP3A4MAPK1MEN1 | |
| SCHEMBL6741316 | 0.87 | PIK3CA (0.49) | HTR6PDK2GPR119TGFBR1PIK3CA | |
| SCHEMBL6745761 | 0.86 | HTR6 (0.69) | HTR6PDK2GPR119TGFBR1PIK3CA | |
| SCHEMBL6743416 | 0.86 | HTR6 (0.58) | HTR6POLBCYP3A4KMT2ARORC | |
| SCHEMBL6744352 | 0.84 | MAPT (0.50) | HTR6PDK2GPR119TGFBR1PIK3CA | |
| SCHEMBL6745742 | 0.83 | HTR6 (0.61) | HTR6POLBCYP3A4KMT2A | |
| SCHEMBL3128669 | 0.81 | HTR6 (0.79) | HTR6 | |
| SCHEMBL6747464 | 0.81 | HTR6 (0.79) | HTR6 | |
| Hydrochloric Acid SCHEMBL6833514 | 0.80 | HTR6 (0.78) | HTR6 | |
| SCHEMBL3618644 | 0.80 | TGFBR1 (0.51) | HTR6PDK2GPR119TGFBR1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | PHARMACIA & UPJOHN COMPANY | 2004-02-12 | — | — | US | disclosed |
| US-20040014966-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2004-01-22 | — | — | US | disclosed |
| US-20030225065-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-6586592-B2 | Labled isotopes of phenyl 4-(1,4-diazepin-1-yl)-2-amino phenyl sulfone derivatives used in nuclear magnetic resonance imaging and positron emission tomography | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-6579870-B2 | 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity | PHARMACIA & UPJOHN COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20020115660-A1 | Bis -arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-20020037892-A1 | Bis-arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PMP22, NLN, INA | HTR6 221/4885PDK2 1547/4885GPR119 1314/4885 |
| US-20020037892-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | HTR6 35/4885PDK2 1346/4885GPR119 710/4885 |
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | HCRTR2, HCRTR1, CNR1 | HTR6 76/4885PDK2 2967/4885GPR119 20/4885 |
| US-20020115660-A1 | Bis -arylsulfones | PMP22, ARSA, CLN6 | HTR6 35/4885PDK2 1346/4885GPR119 710/4885 |
| US-20030225065-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | HTR6 35/4885PDK2 1346/4885GPR119 710/4885 |
| US-20040014966-A1 | Bis-arylsulfones | NPSR1, ARSA, SLC18A2 | HTR6 69/4885PDK2 2628/4885GPR119 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.